Fusion Pharmaceuticals Inc.
DelistedCIK 1805890fmd_0SMZ04HAR22WMEBTDSNFZ26AQJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Mar 31, 2024, 21 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Total revenues | – | – | 1 | 1 | 2 |
| Net interest income | 1 | 0 | 0 | – | – |
| Research and development | 11 | 17 | 56 | 59 | 70 |
| Total operating expenses | 18 | 38 | 83 | 89 | 101 |
| Operating income | (18) | (38) | (82) | (88) | (99) |
| Other non-operating income (expense) | 2 | (38) | 1 | (1) | 5 |
| Income before taxes | (16) | (76) | (81) | (89) | (94) |
| Income tax expense | 0 | 3 | (0) | (2) | 1 |
| Net income from continuing operations | (16) | (78) | (81) | (89) | (94) |
| Net income | (16) | (78) | (81) | (88) | (95) |
| Net income to common shareholders | (16) | (80) | (81) | – | – |